45780 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices 

in a previous notice published in the 

Federal Register on September 23, 1975 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17976 Filed 8–4–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on June 2, 

2008, Wildlife Laboratories, 1401 Duff 

Drive, Suite 400, Fort Collins, Colorado 

80524, made application by renewal to 

the Drug Enforcement Administration 

(DEA) to be registered as an importer of 

Etorphine Hydrochloride (9059), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance for sale to its 

customers. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than September 5, 2008. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745), all applicants for 

registration to import a basic class of 

any controlled substance listed in 

schedule I or II are, and will continue 

to be, required to demonstrate to the 

Deputy Assistant Administrator, Office 

of Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a), 21 U.S.C. 823(a), and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: July 29, 2008. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E8–17977 Filed 8–4–08; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with Title 21 

Code of Federal Regulations (CFR), 

1301.34(a), this is notice that on March 

26, 2008, BA Research International 

LLC, 10550 Rockley Road, Suite 150, 

Houston, Texas 77099–0000, made 

application to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in 

schedules I and II: 

Drug Schedule 

4-Methylaminorex (cis isomer) 

(1590).

I 

Gamma Hydroxybutyric Acid 

(2010).

I 

Methaqualone (2565) .................... I 

Ibogaine (7260) ............................. I 

Drug Schedule 

Lysergic acid diethylamide (7315) I 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ...... I 

Cannabidiol (7372) ....................... I 

Mescaline (7381) .......................... I 

4-Methyl-2,5-dimethoxyamphetamine (7395).I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

3,4-Methylenedioxymethamphetamine (7405).I 

Peyote (7415) ............................... I 

Bufotenine (7433) ......................... I 

Diethyltryptamine (7434) ............... I 

Dimethyltryptamine (7435) ............ I 

Psilocybin (7437) .......................... I 

Etorphine (except HCL) (9056) .... I 

Heroin (9200) ................................ I 

Normorphine (9313) ...................... I 

Alphacetylmethadol except levoalphacetylmethadol (9603).I 

Amphetamine (1100) .................... II 

Methamphetamine (1105) ............. II 

Methylphenidate (1724) ................ II 

Amobarbital (2125) ....................... II 

Pentobarbital (2270) ..................... II 

Secobarbital (2315) ...................... II 

Phencyclidine (7471) .................... II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Diprenorphine (9058) .................... II 

Etorphine HCL (9059) ................... II 

Oxycodone (9143) ........................ II 

Hydromorphone (9150) ................. II 

Diphenoxylate (9170) .................... II 

Ethylmorphine (9190) ................... II 

Levorphanol (9220) ....................... II 

Dextropropoxyphene, bulk (nondosage forms) (9273).II 

Thebaine (9333) ........................... II 

Opium, raw (9600) ........................ II 

Opium, powdered (9639) .............. II 

Levo-alphacetylmethadol (9648) .. II 

Oxymorphone (9652) .................... II 

Fentanyl (9801) ............................. II 

Hydrocodone (9193) ..................... II 

Meperidine (9230) ......................... II 

Methadone (9250) ........................ II 

Morphine (9300) ........................... II 

The company plans to import 

analytical reference standards for 

analytical testing of blood samples from 

clinical trials. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43 and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

mstockstill on PROD1PC66 with NOTICES